Mar 30, 2014New Long-term Data Demonstrate Patients with Mild Heart Failure Sustained Lower Mortality Rates After Receiving Boston Scientific CRT DefibrillatorsMADIT-CRT Long-Term Follow-up Results Presented at the American College of Cardiology and Published in the New England Journal of Medicine
In the longest follow-up to date of cardiac resynchronization therapy (CRT) for mild heart failure patients, Boston Scientific Corporation's (NYSE: BSX) exclusively sponsored and landmark...
Mar 14, 2014First implant took place in France, at the Nouvelles Cliniques Nantaises in Nantes
Boston Scientific Corporation (NYSE: BSX) announces CE Mark approval and European market launch of the INGEVITY™ family of magnetic resonance imaging (MRI) compatible pacing leads. Pacing leads...
Mar 12, 2014Newest Bare Metal Stent Technology Features Advanced Architecture and Provides Physicians with Enhanced Treatment Option for Patients
Continuing to advance leading stent technology, Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval for the REBEL™ Platinum Chromium Coronary Stent System, the company's...
Feb 24, 2014Dystonia Europe And The European Parkinson’s Disease Association (Epda) Partner With Boston Scientific In Advancing Parkinson’s And Dystonia Care
Dystonia Europe (DE) and The European Parkinson’s Disease Association (EPDA) announced today that they are collaborating with Boston Scientific Corporation (NYSE:BSX), a global medical...
Dec 17, 2013Boston Scientific Announces CE Mark Approval And First Implants Of Its Next-Generation X4 Quadripolar CRT-D Systems
Boston Scientific Corporation (NYSE: BSX) has received CE Mark approval of its X4 line of quadripolar CRT-D systems, including the AUTOGEN™ X4, DYNAGEN™ X4, and INOGEN™ X4 cardiac...